Medindia

X

Idiopathic Pulmonary Fibrosis Market 2025 Epidemiology Forecasts

Tuesday, July 26, 2016 Respiratory Disease News J E 4
Advertisement

PUNE, India, July 26, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025" to its store providing overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.

Complete report on idiopathic pulmonary fibrosis market epidemiology forecast to 2025 of 55 pages with 15 tables and 13 figures is now available at http://www.rnrmarketresearch.com/epicast-report-idiopathic-pulmonary-fibrosis-epidemiology-forecast-to-2025-market-report.html .

Epidemiologists forecast that the diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.

The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF is more common in men and the incidence and prevalence of IPF typically increases with advancing age.

Epidemiologists used data from large comprehensive healthcare databases and country-specific studies published in peer-reviewed journals to estimate the diagnosed incident and diagnosed prevalent cases of IPF in addition to sources that provided data for cases confirmed through both biopsy of the lung and HRCT. Diagnosed incident and diagnosed prevalent cases were further segmented by age and sex to provide more detailed characteristics regarding the diseased population. The use of studies with consistent methodology across the 7MM provides a significant measure to compare the underlying burden of IPF across the 7MM. Additionally, GlobalData epidemiologists provided the diagnosed incident and diagnosed prevalent cases of IPF in the 7MM, except Japan, segmented by severity (mild, moderate, and severe) based on GAP index, which can be of importance for predicting the prognosis and course of treatment.

Order a copy of Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=629934 .

Another newly published market research titled Pulmonary Embolism - Pipeline Review, H1 2016 to its database. The research provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects.  Companies Involved in Therapeutics Development are Accu-Break Pharmaceuticals, Inc., Bristol-Myers Squibb Company and F. Hoffmann-La Roche Ltd. Complete report on Pulmonary Embolism Pipeline market research report of 54 pages is available at http://www.rnrmarketresearch.com/pulmonary-embolism-pipeline-review-h1-2016-market-report.html .

Explore more reports on Pulmonary therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/pulmonary-therapeutics .

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel: +1-888-391-5441 sales@rnrmarketresearch.com

SOURCE RnR Market Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Ashley Kaltwasser and EHP Labs sued by Sports Nutr...
S
Pen-Y-Bont Health 'Helping Patients 24/7' Through ...